MEI Pharma shareholders approve reverse stock split authorization and other proposals at annual meeting

Proposal 5. – Ratification of Appointment of BDO USA, LLP. Proposal 5 was to ratify the appointment of BDO USA, LLP, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending June 30, 2023. The proposal was approved. For Against Abstain 78,700,571 689,734 5,192,069

Proposal 3. – Approval of an Amendment to the Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split. Proposal 3 was to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock by a ratio of any whole number between 1-for-10 and 1-for-20, at any time prior to June 30, 2023, with the exact ratio to be set within that range at the discretion of our Board of Directors, without further approval or authorization of the Company’s stockholders. The proposal was approved. For Against Abstain 68,495,443 12,271,441 3,815,490

Proposal 4. – Advisory Vote on Executive Compensation. Proposal 4 was to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement. The proposal was approved. For Against Abstain Broker Non- Votes 43,376,299 6,778,476 4,147,548 30,280,051

Proposal 1. – Election of Director. The following individual, who was named as a nominee in the Company’s definitive proxy statement relating to the Annual Meeting, was elected by the Company’s stockholders by a plurality of votes cast to serve a three-year term on the Company’s Board of Directors which will expire at the Company’s annual meeting of stockholders for fiscal year 2026. Information on the vote relating to the director standing for election is set forth below: Nominee For Withheld Broker Non- Votes Dr. Thomas C. Reynolds 49,024,478 5,277,845 30,280,051

Proposal 2. – Approval of Amended and Restated 2008 Stock Omnibus Equity Compensation Plan. Proposal 2 was to approve the Amended and Restated MEI Pharma, Inc. 2008 Omnibus Equity Compensation Plan (the “2008 Equity Plan”) to increase the number of shares of common stock that may be subject to awards and to make certain other changes to the plan terms included in the plan document attached as Annex A to the definitive proxy statement relating to the Annual Meeting. The proposal was approved. For Against Abstain Broker Non- Votes 44,169,994 5,892,604 4,239,725 30,280,051